Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
0.00% $54.99
Last updated: 7 aug 2022 - 23:25
TimeZone: America/New_York
FUNDAMENTALS | |
---|---|
MarketCap: | 1 342.82 mill |
EPS: | -6.59 |
P/E: | 0.000 |
Earnings Date: | Aug 03, 2022 |
SharesOutstanding: | 24.42 mill |
Avg Daily Volume: | 0.651 mill |
RATING 2022-07-01 |
---|
B+ |
Neutral |
RATINGDETAILS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
DISCOUNTED CASH FLOW VALUE |
---|
$62.89 (14.37%) $7.90 |
Date: 2022-08-08 |
Expected Trading Range (DAY) |
---|
$ 54.81 - 55.17 ( +/- 0.33%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-07-01 | Vivo Opportunity, Llc | Sell | 75 749 | Series A Warrants |
2022-07-01 | Vivo Opportunity, Llc | Sell | 75 749 | Series A Warrants |
2022-07-01 | Orbimed Advisors Llc | Sell | 170 437 | Series A Warrants |
2022-07-01 | Orbimed Advisors Llc | Sell | 170 437 | Series A Warrants |
2022-07-01 | Ashiya Mona | Sell | 170 437 | Series A Warrants |
INSIDER POWER |
---|
-39.99 |
Last 100 transactions |
Buy: 5 559 417 | Sell: 11 118 209 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $54.99 (0.00% ) |
Volume | 0.000 mill |
Avg. Vol. | 0.651 mill |
% of Avg. Vol | 0.000 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
Date | Signal | @ | Closed | % | Jul 25 - 09:43 | buy | $54.99 | N/A | Active |
---|
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).